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Abstract 
OBJECTIVE  
Nighttime blood pressure (BP) and albuminuria are two important and independent 
predictors of cardiovascular morbidity and mortality. Here, we examined the 
quantitative differences in nighttime systolic BP (SBP) across albuminuria levels in 
patients with and without diabetes and chronic kidney disease.  
RESEARCH DESIGN AND METHODS  
16,546 patients from the Spanish Ambulatory BP Monitoring Registry cohort (mean age 
59.6 years, 54.9% men) were analyzed. Patients were classified according to estimated 
glomerular filtration rate (eGFR), as ≥60 mL/min/1.73m2 or <60 mL/min/1.73m2 (low 
eGFR), and to urine albumin-to-creatinine ratio, as normoalbuminuria (<30 mg/g), high 
albuminuria (30–300 mg/g), or very high albuminuria (>300 mg/g). Office and 24 hours 
BP were determined with standardized methods and conditions.  
RESULTS  
High albuminuria was associated with a statistically significant and clinically 
substantial higher nighttime SBP (+6.8 mmHg higher than in normoalbuminuria; 
P<0.001). This association was particularly striking at very high albuminuria among 
patients with diabetes and low eGFR (+16.5 mmHg; P<0.001). Generalized linear 
models showed that after full adjustment for demographic, lifestyles, and clinical 
characteristics, nighttime SBP was 4.8 mmHg higher in patients with high albuminuria 
than in those with normoalbuminuria (P<0.001), and patients with very high 
albuminuria had a 6.1 mmHg greater nighttime SBP than those with high albuminuria 
(P<0.001). These differences were 3.8 and 3.1 mmHg, respectively among non-diabetic 
patients, and 6.5 and 8 mmHg among diabetic patients (P<0.001).  
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CONCLUSIONS  
Albuminuria in hypertensive patients is accompanied by quantitatively striking higher 
nighttime SBP, particularly in those with diabetes with very high albuminuria and low 
eGFR. 
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Hypertension is the worldwide cause of death as repeatedly shown by the Global 
Burden of Disease Study in 2002 (1) and 2012 (2). It is also known that nighttime blood 
pressure (BP) is a stronger predictor of cardiovascular disease (CVD) than daytime BP 
(3-6). Moreover, it is well established that elevated BP is the most important risk factor 
for progression of kidney injury towards end-stage renal disease (ESRD) (7, 8). 
Albuminuria, i.e. an increased amount of albumin in the urine, is the most common 
marker of renal injury in patients with chronic kidney disease (CKD) and can be present 
with preserved or diminished estimated glomerular filtration rate (eGFR) (9). 
Importantly, several lines of evidence suggest that albuminuria is associated not only 
with CKD progression, but also with the development of CVD and ESRD (10-12). 
Several studies have associated the circadian rhythm of BP to 
proteinuria/albuminuria in patients with diabetes and/or CKD (13-17). Additionally, 
previous data from our group showed that high albuminuria (30-300 mg/g creatinine) is 
associated with nighttime systolic BP (SBP) in treated and untreated patients with 
hypertension and in resistant hypertension (18, 19). These findings prompted us to 
analyze the relationship between nighttime BP and very high albuminuria (>300 mg/g 
creatinine) in patients with hypertension accompanied by CKD or diabetes drawn from 
the large Spanish Ambulatory Blood Pressure Monitoring (ABPM) Registry (20). We 
were particularly interested in quantifying the difference in nocturnal BP across 
albuminuria groups in patients with and without diabetes or CKD, which to the best of 
our knowledge has not been specifically addressed.    
RESEARCH DESIGN AND METHODS  
Study Population 
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The Spanish ABPM Registry was initiated to promote the use of ABPM mostly in 
primary health care. Details of the Registry characteristics have been reported elsewhere 
(20). Briefly, physicians and nurses from a selected group of primary care centers and 
specialized units received specific training in the technique of ABPM and how to use a 
purpose-built internet-based platform that receives ABPM registries and relevant 
clinical information. The general indications for ABPM according to the European 
Society of Hypertension Guidelines for BP measurement were used (21-23), and 
included suspected white-coat hypertension, resistant hypertension, assessment of 
dipping status, assessment of drug treatment efficacy, labile or borderline hypertension, 
untreated hypertension, and high-risk hypertension. The protocol was approved by  
various Ethics Committees of the participating centers in Spain. All patients gave 
informed consent before ABPM recording. All ABPM reports obtained in real-time, 
along with corresponding medical information, are uploaded in the internet-based 
platform and stored in an external database. 
The present study is a cross-sectional analysis of 16,546 patients included in the 
Registry from December 2009 to December 2014, with valid ABPM readings and 
complete information for determination of albuminuria, diabetes and CKD status, as 
described below. Every patient underwen the same examinations as any hypertensive 
patient entering a primary care centers (20).  
 
Measurements and Definitions 
Office BP was measured twice with calibrated mercury sphygmomanometers or 
validated oscillometric devices available at the study centers with adequate cuff size, 
according to European Society of Hypertension/European Society of Cardiology 
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recommendations (21). ABPM was performed after the clinic visit using a validated 
SpaceLabs 90207 device. The monitor recorded BP at 20-minute intervals for the 24-
hour period. Recordings were performed preferentially on working days, and the 
patients maintained their usual activities. Valid measurements were those fulfilling 
80% successful recordings, at 1 valid measurement/hour, and ≥24-hour duration. 
Daytime and nighttime periods were defined individually according to patients’ self-
reported data of going-to-bed and getting-up times. Hypertension was defined as office 
systolic/diastolic BP (SBP/DBP) 140/90 mmHg or current treatment with 
antihypertensive drugs. Hypertension control was defined for office values as <140/90 
mmHg, control of ambulatory BP was defined as mean 24-hour BP <130/80 mmHg, 
and daytime and nighttime BP control as values <135/85 and <120/70 mmHg, 
respectively (21). Dipping status was defined according to international guidelines (21). 
Nondipper (or reduced dipper) was defined as the finding of a nocturnal BP fall of 
<10% of daytime values, and riser (or reverse dipper) was a nocturnal BP raise.  
The eGFR value was estimated from serum creatinine levels with the CKD-EPI 
(Chronic Kidney Disease Epidemiology Collaboration) equation (24). Serum creatinine 
was measured at local sites and multiplied by 0.95 because it was not standardized to 
isotope dilution mass spectrometry (25). Urinary albumin excretion was measured at 
local laboratories by turbidimetry according to current recommended standards and was 
reported as albumin-creatinine ratio (ACR) in mg/g of creatinine. Two morning urine 
samples were obtained from in every patient and the average of the two was considered 
as the value of albuminuria. Laboratory data were obtained within 2 months of the index 
visit. Patients were initially classified according to eGFR as ≥60 or <60 mL/min/1.73 
m
2
 (low eGFR), and then according to urine albumin to creatinine ratio as micro or high 
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albuminuria (30–300 mg/g), and macro or very high albuminuria (>300 mg/g) following 
KDIGO (26).  
Additional information based on interviews and physical examination of patients 
at the time of the visit and on data from clinical records was defined and measured in 
accordance with consensus European Society of Hypertension/European Society of 
Cardiology (ESH/ESC) 2007(22) and 2013 (21) guidelines, and included the following: 
age, sex, weight, height, body mass index (BMI), abdominal circumference, smoking, 
dyslipidemia, diabetes (defined based on known history of diabetes, use of antidiabetic 
drugs or fasting glucose values above 126 mg/mL (27)), family history of premature 
cardiovascular disease (aged <55 years in men or <65 years in women), and associated 
clinical conditions (including documented presence of coronary heart disease, 
cerebrovascular disease, or heart failure). Stratification of cardiovascular risk of patients 
was performed following international guidelines (21, 22), which classifies 10-year risk 
of cardiovascular mortality as low risk (<1%), moderate risk (1-4%), high risk (5-10%), 
and very high risk (>10%).  
 
Statistical Methods  
Differences in sociodemographic and clinical characteristics between albuminuria 
groups were evaluated by analysis of variance (ANOVA) for continuous variables and 
χ2 test for categorical variables. In particular, we calculated and tested differences in 
nighttime and daytime BP between the 3 albuminuria groups (normo, micro, and 
macro), in the total sample and in the 2 eGFR-based subgroups. Since of all BP 
variables, only nighttime SBP is independently associated with high and very high 
albuminuria, and this variable was the objective of the present study, we focused on 
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nocturnal SBP for further analyses. We also calculated the percentage of SBP circadian 
patterns (dippers, nondippers, and risers), and the night/day SBP ratio according to 
albuminuria and eGFR groups and diabetes status. 
A generalized linear model of the association between nighttime SBP (main 
variable of interest) and albuminuria (3 groups) was built adjusting for age (continuous), 
sex, BMI (continuous), waist circumference (continuous), smoking (current, ex-smoker, 
never), diabetes (yes/no), blood glucose levels, dyslipidemia (yes/no), cardiovascular 
disease (yes/no), antihypertensive drug treatment (yes/no), eGFR (continuous), 
nighttime DBP (continuous), daytime SBP (continuous), daytime DBP (continuous), 
clinic SBP (continuous), and clinic DBP (continuous). Separate adjusted models were 
also built for patients with and without diabetes. As a sensitivity analysis, we performed 
more parsimonious models, excluding adjustment for waist circumference, diabetes 
status, and clinic BP, thus dealing with possible collinearity among some covariates. 
Also, these parsimonious models were analyzed separately according to diabetes status. 
P values of <0.05 was considered statistically significant. Analyses were performed 
using the SPSS version 17 (IBM, Armonk, NY) computer software program. 
 
RESULTS  
Baseline characteristics   
A total of 16,546 patients (mean age 59.6 years, 54.9% males) were included in this 
analysis. Most of them (93%) were hypertensive. Mean clinic SBP/DBP was 149.6/87.0 
mmHg, and mean 24-h SBP/DBP was 129.3/76.1 mmHg. SBP, but not DBP, was 
significantly higher among albuminuric than normoalbuminuric patients (P<0.001). 
Some 25.3% of the population had diabetes. As presented in Table 1, 84% had 
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normoalbuminuria, 13.7% had high albuminuria (30-300 mg/g), and 2.4% had very high 
albuminuria (>300 mg/g). Patients with high albuminuria were characterized by 
significantly older age (P<0.001), and higher BMI (P<0.001) and waist circumference 
(P<0.001), but these differences were not clinically meaningful. These differences were 
more marked in patients with very high albuminuria than in patients with normo and 
high albuminuria. The presence of albuminuria was accompanied by a significantly 
higher prevalence of cardiovascular risk factors and high/very high cardiovascular risk 
(P<0.001), with the exception of family history of early CVD. Serum glucose, 
creatinine, triglycerides and LDL cholesterol values were significantly higher when 
albuminuria was elevated (P<0.001), but generally of little clinical meaning. eGFR 
measured by CKD-EPI was significantly lower when albuminuria was present, with 
more than 40% of patients with high albuminuria and more than 65% of those with very 
high albuminuria presenting eGFR <60 mL/min/1.73 m
2
.  
As can also be seen in Table 1, the percentage of patients with office BP under 
control was lower when albuminuria was present (P=0.002), and the same was true for 
ABPM data during daytime, nighttime and 24 hours (P<0.001). The percentage of 
dipper pattern on ABPM was significantly lower and that of nondipper higher in 
albuminuric patients (P<0.001). The percentage of risers increased significantly from 
normoalbuminuria to very high albuminuria (P<0.001). Finally, Table 1 presents the 
different antihypertensive medications received by the patients. Both the number of 
drugs and the percentage of most antihypertensive classes were higher in albuminuric 
patients, and the use of renoprotective agents (i.e. blockers of the renin-angiotensin-
system) in patients with albuminuria was slightly over 60%.        
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ABPM findings according to presence of CKD or diabetes   
Table 2 shows nighttime and daytime SBP and DBP values in the whole group 
according to eGFR category and albuminuria status. A significant increase for nighttime 
and daytime SBP across progressive albuminuria groups (from normoalbuminuria to 
high and very high albuminuria) in all subjects and eGFR categories was noted (all 
P<0.001). In the total sample, DBP showed a variable pattern with significant albeit 
clinically minor increases during the night and a decrease during the day across the 
albuminuria groups. Only nighttime DBP changes reached statistical significance in 
eGFR subgroups (P<0.001).  In addition, when compared with the normoalbuminuria 
group, the mean increment in nighttime SBP among patients with very high albuminuria 
was 14.3 mmHg in the whole group, 12.0 mmHg in the eGFR >60 ml/min/1.73 m
2
 
group, and 13.9 mmHg in the eGFR <60 ml/min/1.73 m
2
 group. This compared with 
8.9, 7.0, and 10.0 mmHg increments in daytime SBP in the 3 groups, respectively. 
Among the untreated and treated patients, the pattern of nighttime and daytime BP 
values across albuminuria and eGFR groups was similar in magnitude and direction to 
that in the whole sample, but in general statistical significance was only reached for 
SBP values (Supplementary Table 1).  
Data for patients with and without diabetes are presented in Table 3. As depicted 
in the table, a significant increase for nighttime and daytime SBP across progressive 
albuminuria groups was observed in nondiabetic patients (P<0.001). In the whole group 
the mean increase in nighttime SBP was 8.9 mmHg and 5.0 mmHg in patients with very 
high or high albuminuria, respectively, compared with normoalbuminuric patients. In 
the eGFR ≥60 ml/min/1.73 m2 group the increases were 5.7 and 3.8 mmHg, 
respectively, and in the eGFR <60 ml/min/1.73 m
2
 they were 8.8 and 5.8 mmHg, 
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respectively. For daytime SBP, the differences were smaller, as noted in Table 3. Data 
for diabetes patients, and shows a similar behavior for nighttime and daytime SBP, with 
significant increases (Table 3; P<0.001), but DBP only slightly increased during 
daytime in CKD stage 3-5. The mean increment in nighttime SBP for the whole group 
of diabetic patients was 16.0 mmHg for patients with very high vs. normoalbuminuria. 
In the eGFR ≥60 ml/min/1.73 m2 group, the increase was 13.5 mmHg, and in the eGFR 
<60 ml/min/1.73 m
2 
group it was 16.5 mmHg. For daytime SBP the differences were 
11.0, 8.9, and 12.5 mmHg, respectively (Table 3). Overall, the increasing trend in 
nocturnal SBP across albuminuria groups was significantly higher in individuals with 
diabetes than in those without diabetes, in the total and in both eGFR groups (P<0.001). 
In addition, the proportion of nondipper and riser patients and the night/day BP ratio 
generally increased across albuminuria groups, although more notably in patients with 
low eGFR or diabetes (all P<0.001) (Tables 2 and 3, and Figure 1). 
 
Multivariable analysis of albuminuria with nighttime blood pressure  
The generalized linear model showed that after full adjustment for demographic 
characteristics, lifestyles, and clinic variables (including diabetes, blood glucose, 
cardiovascular disease, eGFR, BP medication, and clinic and daytime BP), nighttime 
SBP was 4.8 mmHg higher in patients with high albuminuria than in those with 
normoalbuminuria, and patients with very high albuminuria had a 6.1 mmHg greater 
nighttime SBP than those with high albuminuria (Table 4). These differences were 3.8 
and 3.1 mmHg, respectively among non-diabetic patients, and 6.5 and 8 mmHg among 
diabetic patients (P<0.001) (Table 4). Multivariable models for daytime BP failed to 
12 
 
attain statistical significance (data not shown). When the parsimonious model was used, 
the aforementioned general pattern was quite similar (Table 4).   
 
CONCLUSIONS  
These data demonstrate that the presence of high or very high albuminuria is associated 
with significant and substantial increases in nighttime systolic BP, irrespective of the 
level of eGFR and the existence of diabetes. In particular, nighttime SBP is significantly 
and substantially higher in the presence of very high albuminuria in patients with CKD 
and diabetes (+16.5 mmHg) when compared with normoalbuminuric diabetes patients. 
Even after full adjustment for demographic, lifestyle, and clinic covariates (including 
eGFR, glucose levels, BP medication, and clinic and daytime BP), nighttime SBP 
remained as a significant, independent, and clinically substantial factor associated with 
albuminuria, amounting to 14.5 mmHg higher pressure among very high albuminuria 
patients with diabetes than among their normoalbuminuria counterparts. Daytime SBP 
was also significantly elevated in patients with albuminuria and particularly in those 
with diabetes, at a lower albeit still marked increase (up to +12.5 mmHg). Indeed, of all 
BP variables, only nighttime SBP was independently associated with increased 
likelihood of high and very high albuminuria. A similar pattern for increase in nighttime 
and daytime SBP with albuminuria status was observed in non-diabetic patients, 
although the differences were much smaller. The presence or absence of 
antihypertensive treatment did not contribute to change the BP pattern described here. 
Consistent with our results, several previous studies described an association between 
albuminuria and circadian ambulatory BP in patients with diabetes or CKD (13-17). 
However, unlike our study most of the previous studies had relatively small sample 
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sizes (a few hundred patients), and, more importantly, they focused on night-time non-
dipping or isolated nocturnal hypertension, whereas we used nighttime BP as a 
continuous variable, allowing for quantification of nocturnal BP differences across 
albuminuria groups. In addition, we described the existence of a correlation between 
high albuminuria and nocturnal SBP levels in previous works (18, 19), but these 
relationships were studied specifically in hypertensive and resistant hypertensive 
patients without specific consideration of diabetes or CKD, and were not focused on the 
quantitative differences in BP according to renal and diabetes status applied in the 
present study. Thus, to our knowledge, this is the first description of a quantitatively 
very relevant higher nighttime systolic BP in patients with high and very high levels of 
albuminuria compared with normoalbuminuria, particularly in diabetic CKD.  
What is the risk of elevated nighttime SBP? Elevated nighttime BP levels are 
accompanied by the highest cardiovascular risk compared with elevation of any ABPM 
component (3-6, 28), and the existence of a nondipping status is also characterized by 
the worst prognosis (29-31). In a previous study (19), we found that the worst profile 
related to nighttime BP was present in patients exhibiting simultaneously nondipping 
and nocturnal hypertension. This is also true for BP risers, who present the highest 
levels of nighttime BP and consequently the highest risk (23).  
We also found that nondippers and risers were more frequent in patients with more 
advanced renal disease and that nocturnal hypertension was associated with high 
albuminuria. The different behavior of daytime and nighttime DBP as compared with 
SBP indicates the presence of an increase in pulse pressure (the difference between SBP 
and DBP). In the crosstalk between large and small arteries this situation allows the 
transmission of pulsatile pressure wave facilitating an enhancement of small vessel 
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damage at the cardiac, brain and kidney level. In the kidney, this event may facilitate the 
development of albuminuria (32). In this study, we analyzed in a comprehensive and 
detailed manner, the association between nocturnal and daytime ambulatory SBP and 
DBP on the one hand, and albuminuria on the other hand, in a large sample of patients 
with CKD with or without diabetes along their progressive stage.  
What is the risk of albuminuria? High and particularly very high albuminuria is a 
predictor of CVD events and death as well as of the progression of CKD to ESRD (10, 
11, 33). Progression of albuminuria is observed simultaneously with a progressive 
decay in eGFR (34). It is well established that albuminuria and diminished eGFR are 
independently associated with an increased risk for CVD events and death (33, 35). 
Many patients included in this study had both an increase in CVD risk and also an 
enhanced decay progression of eGFR. This enhanced risk was associated in many 
patients with the risk attributable to the presence of diabetes mellitus. This situation of 
risk can also be observed during chronic renin-angiotensin system (RAS) blockade, as 
we previously described (36). The development of new-onset albuminuria during 
chronic administration of an angiotensin-converting enzyme inhibitor (ACEi) or 
angiotensin receptor blocker (ARB) is accompanied by an increased number of CVD 
events (36).           
Our data suggest the presence of a higher risk in diabetic patients with very high 
albuminuria because of the elevation in nighttime and daytime SBP. Hence, it is 
possible that simultaneous control of BP, particularly during nighttime and albuminuria, 
is required to attain the best protection for our patients. Nevertheless, lowering the risk 
of elevated daytime BP in patients with albuminuria should also be considered when 
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treating these subjects.  Clearly, intervention studies are needed to properly address 
these issues.         
What are the consequences of these findings for the prognosis and treatment of 
albuminuria patients? It is possible that if we want to improve the prognosis of 
albuminuria patients, we first need to control the elevated BP, particularly nighttime 
SBP. A progressive drop in BP estimated in the office is followed by a progressive 
decrease in CVD events and death as well as in ESRD (21, 37). By contrast, despite its 
known predictive ability, recent data (38, 39) have questioned the preventive capacity of 
drops in albuminuria. In fact, we probably need to lower the level of albuminuria by 
>50% the figure of albuminuria to see a prevention in CVD events and death (40), while 
lower percentage decreases of clinic systolic BP are accompanied by a significant 
prevention, at least for office BP (41). Finally, these data indicate that, in order to assess 
the appropriateness of nighttime BP control, ABPM performance is required in patients 
with albuminuria because elevated nighttime BP could be present in patients with an 
apparently adequate BP control in the office (42).  
Our study has several limitations. There may have been some selection bias from 
inclusion criteria for conventional ABPM indications; nevertheless the Spanish ABPM 
registry was performed on a large nationwide population sample, providing a real-world 
view of clinical practice on a large scale since physicians and patients were recruited 
across all the geographical communities covered by the national healthcare system in 
Spain. Also, the differences in nocturnal SBP we found seem to be too high to be 
explained by selection bias. Another limitation is the cross-sectional analysis of data, 
which does not allow causal assessment of the relationship studied. However, it seems 
reasonable to think of microvascular damage linking nighttime SBP and high or very 
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high albuminuria, but a prospective study targeting nighttime SBP would be required to 
fully corroborate this. Also, despite exhaustive adjustments and stratifications used, we 
recognize that we have no data showing additive risk of nocturnal BP and albuminuria 
and eGFR. Finally, we lacked data on sleep quality and duration, which may have 
influenced our results. As a positive aspect of our study, we would highlight the large 
number of individuals enrolled, all of them from real clinical practice, which could 
provide helpful descriptive information.  
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Figure Legend.  
Figure 1. Systolic blood pressure night/day ratio according to albuminuria, eGFR 
and diabetes status. eGFR: estimated glomerular filtration rate. Bars indicate 95% 
confidence intervals.   
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Table 1. Sample characteristics according to albuminuria status.  
Variable TOTAL Normo  
albuminuria 
<30 mg/g 
High 
albuminuria 
30-300 mg/g 
Very high 
albuminuria 
≥300 mg/g 
P 
N 16546 13892 2259 395  
Age (years) 59.6±13.6 59.0±13.6 62.3±13.3 64.5±12.5 <0.001 
≥ 60 years 8819(53.3) 7145(51.4) 1399(61.9) 275(69.6) <0.001 
Blood pressure      
Office BP <140/90 mmHg 3818(23.1) 3258(23.5) 494(21.9) 66(16.7) 0.002 
24 hour-ABPM <130/80 mmHg 7464(45.1) 6495(46.8) 864(38.2) 105(26.6) <0.001 
Daytime ABPM <135/85 mmHg 8604(52.0) 7437(53.5) 1027(45.5) 140(35.4) <0.001 
Nighttime ABPM <120/70 mmHg 7012(42.4) 6192(44.6) 739(32.7) 81(20.5) <0.001 
Risk factors     
Body mass index (BMI in kg/m
2
) 29.3±4.9 29.2±4.9 29.9±4.9 30.2±5.5 <0.001 
Obesity (BMI 30 kg/m2) 7128(43.1) 5816(41.9) 1108(49.0) 204(51.6) <0.001 
Waist circumference (cm.) 
   Men 
   Women 
 
101.7±10.5 
96.1±12.3 
 
101.2±10.2 
95.8±12.2 
 
103.7±11.3 
97.9±12.4 
 
105.4±10.6 
99.1±13.1 
 
<0.001 
<0.001 
Abdominal obesity 8640(52.2) 7127(51.3) 1280(56.7) 233(59.0) <0.001 
Family history of premature 
cardiovascular disease  
2695(16.3) 2314(16.7) 334(14.8) 47(11.9) 0.005 
Diabetes mellitus  4185(25.3) 3047(21.9) 920(40.7) 218(55.2) <0.001 
Dyslipidemia  7788(47.1) 6252(45.0) 1259(55.7) 277(70.1) <0.001 
Cardiovacular disease  2055(12.4) 1425(10.3) 472(20.9) 158(40.0) <0.001 
Cardiovascular risk stratification       
Low-moderate  7372(44.6) 6739(48.5) 589(26.1) 44(11.1) <0.001 
High 5440(32.9) 4379(31.5) 925(40.9) 136(34.4) <0.001 
 
 
<0.001 
Very high 3347(20.2) 2415(17.4) 722(32.0) 210(53.2) 
Circadian profile     
Dipper 7815(47.2) 6849(49.3) 852(37.7) 114(28.9) 
Nondipper 6509(39.3) 5357(38.6) 979(43.3) 173(43.8) <0.001 
Riser  2222(13.4) 1686(12.1) 428(18.9) 108(27.3) <0.001 
Analytical values       
<0.001 Triglycerides (mmol/L) 132.2±72.6 128.8±68.6 148.4±88.1 161.3±90.1 
LDL (mmol/L) 127.3±74.6 125.0±74.6 140.4±74.0 136.1±70.1 <0.001 
Glucose (mg/dL) 108.1±31.5 105.9±29.0 118.4±39.1 124.9±47.5 <0.001 
Creatinine (µmol/L) 0.94±0.36 0.91±0.29 1.04±0.42 1.45±1.10 <0.001 
eGFR by CKD-EPI (mL/min/1.73 m
2
) 75.8±23.7 77.5±22.5 69.1±26.8 52.6±27.1 <0.001 
eGFR by CKD-EPI <60 (mL/min/1.73 
m
2
) 
4870(29.4) 3622(26.1) 980(43.4) 268(67.8) <0.001 
Antihypertensive drugs       
Patients treated  10906(65.9) 8799(63.3) 1780(78.8) 328(83.0) <0.001 
Number of drugs in treated 2.2±1.1 2.1±1.1 2.5±1.2 2.8±1.4 <0.001 
Diuretics 3747(34.4) 2998(34.1) 626(35.2) 123(37.5) 0.143 
β-blockers  1817(16.7) 1456(16.5) 313(17.6) 48(14.6) 0.865 
Calcium channel blockers 
(Dihydropyridines) 
2144(19.7) 1609(18.3) 432(24.3) 103(31.4) <0.001 
Calcium channel blockers (non-
dihydropyridines) 
343(3.1) 265(3.0) 64(3.6) 14(4.3) 0.081 
ACE inhibitors  2260(20.7) 1841(20.9) 350 (19.7) 69(21.0) 0.413 
ARBs 3861(35.4) 2986(33.9) 737(41.4) 138(42.1) <0.001 
Direct renin inhibitors 71 (0.7) 44 (0.5) 20 (1.1) 7 (2.1) <0.001 
α-blockers  612(5.6) 401(4.6) 166(9.3) 45(13.7) <0.001 
Data are given as mean ± SD or n (%). 
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Table 2. Nighttime and daytime blood pressure values and dipping proportion according to estimated glomerular filtration rate and 
albuminuria status. 
 Total eGFR >60 ml/min/1.73 m2 eGFR <60 ml/min/1.73 m2 (CKD Stage3-5) 
N 16546 11676 4870 
 Normoalbu
minuria 
<30 mg/g 
High 
albuminuria 
30-300 
mg/g 
Very high 
albuminuria 
≥300 mg/g 
 
 
Normoalbu
minuria 
<30 mg/g 
High 
albuminuria 
30-300 
mg/g 
Very high 
albuminuria 
≥300 mg/g 
 Normoalbu
minuria  
<30 mg/g 
High 
albuminuria 
30-300 
mg/g 
Very high 
albuminuria 
≥300 mg/g 
 
N (%) 13892(84.0) 2259(13.7) 395(2.4)  10270(88.0) 1279(11.0) 127(1.1)  3622(74.4) 980(20.1) 268(5.5)  
Nighttime 
SBP, 
mmHg 
119.1±15.0 125.9±18.2 133.4±19.9 P<0.001 118.5±14.7 124.6±17.8 130.5±20.1 P<0.001 120.9±15.6 127.5±18.7 134.8±19.7 P<0.001 
Nighttime 
DBP, 
mmHg 
67.9±10.1 69.9±11.2 70.0±11.0 P<0.001 68.3±9.9 69.8±10.8 68.5±10.0 P<0.001 67.0±10.4 67.8±11.7 69.5±11.0 P<0.001 
Daytime 
SBP, 
mmHg 
131.6±13.4 135.7±16.2 140.5±17.5 P<0.001 131.7±13.2 135.3±15.6 138.7±15.5 P<0.001 131.4±14.0 136.2±16.9 141.4±18.3 P<0.001 
Daytime 
DBP, 
mmHg 
79.1±10.6 78.2±11.5 77.6±11.1 P<0.001 80.0±10.3 79.9±11.1 80.1±10.6 P=0.899 76.6±10.9 76.0±11.6 76.4±11.2 P=0.384 
Dippers, % 49.3 37.7 28.9 <0.001 51.9 41.4 39.4 <0.001 42.0 32.9 23.9 <0.001 
Nondippers, 
% 
38.6 43.3 43.8 <0.001 37.9 42.8 37.8 <0.001 40.3 44.1 46.6 <0.001 
Risers, % 12.1 18.9 27.3 <0.001 10.2 15.8 22.8 <0.001 17.7 23.1 29.5 <0.001 
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Data are given as N (percentage) for categorical variables and mean ± SD for continuous variables. SBP, systolic blood pressure. DBP, diastolic blood 
pressure. eGFR: estimated glomerular filtration rate. CKD, chronic kidney disease.  
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Table 3. Nighttime and daytime blood pressure values and dipping proportions according to estimated glomerular filtration rate and 
albuminuria status in non-diabetic patients and in diabetic patients. 
 Total eGFR >60 ml/min/1.73 m2 eGFR <60 ml/min/1.73 m2 (CKD Stage3-5) 
 Normo-
albuminuria   
<30 mg/g 
High 
albuminuria 
30-300 mg/g 
Very high 
albuminuria 
≥300 mg/g 
 
P 
Normo-
albuminuria   
<30 mg/g 
High 
albuminuria 
30-300 mg/g 
Very high 
albuminuria 
≥300 mg/g 
 
P 
Normo-
albuminuria   
<30 mg/g 
High 
albuminuria 
30-300 mg/g  
Very high 
albuminuria 
≥300 mg/g 
 
P 
 Non-diabetic patients 
N 12361 8997 3364 
N (%) 10845(87.7) 1339(10.8) 177(1.4)  8170(90.8) 776(8.6) 51(0.6)  2675(79.5) 563(16.7) 126(3.7)  
Nighttime SBP mmHg 118.2±14.6 123.2±17.8 127.1±18.8 <0.001 117.6±14.3 121.4±16.8 123.3±19.0 <0.001 119.9±15.3 125.7±18.8 128.7±18.5 <0.001 
Nighttime DBP mmHg 68.4±10.1 69.8±11.4 70.2±11.5 <0.001 68.7±9.9 70.3±10.7 72.9±9.8 <0.001 67.7±10.5 69.2±12.3 69.1±12.0 <0.001 
Daytime SBP mmHg 131.3±13.3 134.1±15.9 136.5±15.0 <0.001 131.3±13.0 133.5±15.1 133.9±12.3 <0.001 131.1±13.9 135.0±17.0 137.6±15.9 <0.001 
Daytime DBP mmHg 80.1±10.5 80.1±11.5 79.1±11.8 0.343 80.9±10.2 81.5±11.9 83.5±10.2 0.306 77.7±10.9 78.0±11.9 77.4±11.9 0.393 
Dippers, %  51.8 42.0 35.0 0.001 54.1 46.9 47.1 <0.001 44.7 35.2 30.2  <0.001 
Nondippers, % 37.5 42.6 45.2 0.001 36.9 41.6 37.3 <0.001 39.5 43.9 48.4  <0.001 
Risers, % 10.7 15.5 19.8 <0.001 9.0 11.5 15.7 <0.001 15.8 21.0 21.4  <0.001 
 Diabetic patients 
N 4185 2679 1506 
N (%) 3047(72.8) 920(22.0) 218(5.2)  2100(78.4) 503(18.8) 76(2.8)  947(62.9) 417(27.7) 142(9.4)  
Nighttime SBP mmHg 122.5±15.9 129.9±18.1 138.5±19.4 <0.001 121.8±15.7 129.7±18.1 135.3±19.5 <0.001 123.7±16.1 130.1±18.2 140.2±19.2 <0.001 
Nighttime DBP mmHg  66.2±9.8 67.6±10.7 69.9±10.5 <0.001 66.8±9.7 69.0±10.8 70.1±11.4 <0.001 65.1±9.9 66.0±10.5 69.7±10.1 <0.001 
Daytime SBP mmHg 132.8±13.9 138.0±16.3 143.8±18.7 <0.001 133.1±13.9 138.1±16.0 142.0±16.6 <0.001 132.3±14.0 137.9±16.6 144.8±19.8 <0.001 
Daytime DBP mmHg 75.4±10.1 75.5±10.9 76.3±10.4 0.446 76.4±10.0 77.3±10.9 77.9±10.2 0.142 73.2±10.0 73.3±10.6 75.5±10.5 0.040 
Dippers, % 40.4 31.5 23.9 <0.001 43.2 33.0 34.2 <0.001 34.3 29.7 18.3  <0.001 
Nondippers, % 42.2 44.5 42.7 <0.001 42.0 44.5 38.2 <0.001 42.7 44.4 45.1  <0.001 
Risers, % 17.3 24.0 33.5 <0.001 14.8 22.5 27.6 <0.001 23.0 25.9 36.6 <0.001 
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Data are given as N (percentage) for categorical variables and mean ± SD for continuous variables. Albuminuria is expressed as mg/g. SBP, systolic blood 
pressure. DBP, diastolic blood pressure. eGFR: estimated glomerular filtration rate. CKD, chronic kidney disease.  
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Table 4. Generalized linear model of the association between nighttime systolic blood pressure and 
albuminuria according to diabetes status.   
 Albuminuria groups  
 <30 mg/g 30-300 mg/g ≥300 mg/g  
 Mean 95% CI Mean 95% CI Mean 95% CI P value 
Full model        
Total        
Nighttime SBP, mmHg 119.4 119.1-119.6 124.2 123.5-124.8  130.3 128.7-131.9 <0.001 
Non diabetic patients        
Nighttime SBP, mmHg 118.3 118.0-118.5 122.1 121.3-123.0  125.2 122.8-127.5 <0.001 
Diabetic patients        
Nighttime SBP, mmHg 122.5 121.9-123.1 129.0 127.9-130.1  137.0 134.7-139.3 <0.001 
Parsimonious model        
Total        
Nighttime SBP, mmHg 119.5 119.1-119.7 122.4 122.1-122.6 130.4 130.1-130.6 <0.001 
Non diabetic patients        
Nighttime SBP, mmHg 118.8 118-7-118.9 122.8 122.7-122.9 126.8 126.7-126.9 <0.001 
Diabetic patients        
Nighttime SBP, mmHg 122.9 122.7-123.1 128.9 128-7-129.1 135.9 135.7-136.1 <0.001 
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SBP, systolic blood pressure. 95%, 95% confidence interval. Models were adjusted for age, sex, estimated 
glomerular filtration rate, body mass index, waist circumference, tobacco smoking, diabetes (only for the total 
model), blood glucose, dyslipidemia, cardiovascular disease, antihypertensive treatment, clinic systolic BP, 
clinic diastolic BP, daytime systolic BP, daytime diastolic BP, and nighttime diastolic BP. The parsimonious 
model adjusted for the same variables as the full model except for waist circumference, diabetes status, and 
clinic BP.  
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